Clinical-stage biopharmaceutical company GH Research PLC (NASDAQ:GHRS) announced positive results from recent clinical trials of its leading 5-MeO-DMT formula, a therapy candidate for patients ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback